Vapocoolant Spray to Reduce Pain With Nexplanon Insertion
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age14+
SponsorQueen's Medical Center
About this trial
The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.
Eligibility criteria
Qualifiers
At least 14 years or older
Undergoing an etonogestrel implant insertion in the arm in POB1 Suite 1004 or POB2 Suite 402
English speaking
Able and willing to sign the informed consent form and agree to terms of the study
Disqualifiers
Required or requested narcotics, anxiolytics, IV sedation, or general anesthesia for the procedure
Known previous exposure to vapocoolant spray
Nexplanon removal and reinsertion same day during visit in the same arm
Contraindications to vapocoolant spray components (ethyl chloride and 1,1,1,3,3-pentafluoropropane/1,1,1,2-tetrafluroethane)
Trial design
Treatments tested in this trial
- Vapocoolant spray
- Placebo
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Queen's Medical Center
Lead sponsor
Lakshmi Devi and Devraj Sharma Endowment
Collaborator
Source ClinicalTrials.gov